A Single-Center, Randomized, Open-Label, Three-Sequence, Three-Period Crossover Study to Evaluate the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride Injection
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 27
- Locations
- 1
- Primary Endpoint
- Number of reported Adverse Events
Study Overview
Brief Summary
To evaluate the pharmacokinetic interaction of KL0011034 injection in combination with alfentanil hydrochloride injection.To evaluate the safety and tolerability of KL0011034 injection in combination with alfentanil hydrochloride injection.To evaluate the effect of alfentanil hydrochloride injection on the pharmacodynamics of KL0011034 injection.
Detailed Description
This study will be conducted among the participants with moderate-to-severe non-cancerous chronic pain, aiming to evaluate the drug-drug interactions between KL0011034 injection and alfentanil hydrochloride injection. The study consists of two parts:
Part 1 trial:
A single-center, randomized, open, parallel design is adopted to evaluate the safety, tolerability and pharmacodynamic characteristics of the combined use of KL0011034 injection and alfentanil hydrochloride injection.
It is planned to enroll 9 patients with moderate-to-severe non-cancerous chronic pain. All participants will be randomly assigned to one of the three dose groups in a 1:1:1 ratio, with 3 participants in each group. They will complete a single combined administration and undergo pharmacodynamic and safety evaluations.
Based on the results of Part 1 trial, KL0011034 injection will select the maximum dose with acceptable safety among the three doses for the second part of the study.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •patients with moderate-to-severe non-cancerous chronic pain (Age: 18~55 years, NRS score≥4);
- •Body Weight: Male≥50.0kg, Female≥45.0kg; 19.0 ≤BMI≤ 26.0;
- •There were no abnormalities in clinically significant physical examination, vital signs, 12-lead electrocardiogram, chest x-ray, abdominal B-ultrasound, laboratory tests;
Exclusion Criteria
- •Allergy or Drug hypersensitivity;
- •Clinically significant Medical History;
- •History of anesthesia accident, history of serious adverse reactions of anesthesia, or family history of anesthesia accidents, or contraindications to general anesthesia;
- •Dyspnoea or suspected difficult airway, or predicting difficult endotracheal intubation;
- •History of bronchial asthma, chronic obstructive pulmonary disease, sleep apnea syndrome;
- •History of adrenal insufficiency or adrenal tumor or hereditary heme biosynthesis disorder or hereditary acute porphyria;
- •History of any surgery within 3 months;
- •History of any Medication within 14 days;
- •History of any inducers or inhibitors of CYP3A4 or CYP2C19 enzymes within 30 days;
- •History of any clinical study within 3 months;
- •History of any vaccine within 1 month;
- •History of any drug abuse;
- •Needle sickness, Hematosickness;
- •Massive blood loss (> 400 mL) in the past 3 months;
- •Female volunteers are pregnant or lactating;
- •History of unprotected sex within 2 weeks;
- •Heavy smoker ( more than 5 cigarettes/day) within 3 months;
- •History of alcohol abuse,or heavy alcohol intake (more than 14 units a week) within 6 months;
- •Heavy caffeine intake;
- •History of grapefruit, xanthine-rich foods intake within 48 hours;
- •Positive alcohol test;
- •Positive nicotine test;
- •Positive drugs of abuse test result.
Arms & Interventions
Sequence A
Period 1, 6 participants will receive KL0011034 injection; Period 2, 6 participants will receive Alfentanil Hydrochloride Injection; Period 3, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection
Intervention: KL0011034 injection (Drug)
Sequence A
Period 1, 6 participants will receive KL0011034 injection; Period 2, 6 participants will receive Alfentanil Hydrochloride Injection; Period 3, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection
Intervention: Alfentanil Hydrochloride Injection (Drug)
Sequence B
Period 1, 6 participants will receive Alfentanil Hydrochloride Injection; Period 2, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection; Period 3, 6 participants will receive KL0011034 injection;
Intervention: KL0011034 injection (Drug)
Sequence C
Period 1, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection; Period 2, 6 participants will receive KL0011034 injection; Period 3, 6 participants will receive Alfentanil Hydrochloride Injection;
Intervention: KL0011034 injection (Drug)
Sequence B
Period 1, 6 participants will receive Alfentanil Hydrochloride Injection; Period 2, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection; Period 3, 6 participants will receive KL0011034 injection;
Intervention: Alfentanil Hydrochloride Injection (Drug)
Sequence C
Period 1, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection; Period 2, 6 participants will receive KL0011034 injection; Period 3, 6 participants will receive Alfentanil Hydrochloride Injection;
Intervention: Alfentanil Hydrochloride Injection (Drug)
Outcomes
Primary Outcomes
Number of reported Adverse Events
Time Frame: 24 hours post-dose for each period
Safety and tolerability was assessed by the number of volunteers with adverse events.
Secondary Outcomes
- PK parameter Cmax in plasma(24 hours post-dose for each period)
- PK parameter Tmax in plasma(24 hours post-dose for each period)
- PK parameter AUC0-t in plasma(24 hours post-dose for each period)
- PK parameter AUC0-∞ in plasma(24 hours post-dose for each period)
- PK parameter t1/2 in plasma(24 hours post-dose for each period)
- Modified Observer's Assessment of Alertness Sedation (MOAA/S) scale(Day 1 for each period)
- Electroencephalogram bispectrality index (BIS) monitoring(Day 1 for each period)
- Loss of eyelash reflex(Day 1 for each period)
- Modified Aldrete Scoring (Aldrete) Scale(Day 1 for each period)